Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Izokibep in Non-infectious Intermediate, Posterior or Pan-uveitis (LINNAEA)
NCT04706741Phase 2Completed
- Sponsor
- Acelyrin
- Start
- Jan 2022
- Primary completion
- Aug 2022
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of izokibep in intermediate uveitis (IU), posterior uveitis, panuveitis, sponsored by Acelyrin. Started Jan 2022; status: completed.
02
Drugs
izokibep
03
Conditions
intermediate uveitis (IU)posterior uveitispanuveitis
Beyond the preview
Go deeper on NCT04706741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04706741.